tradmap

IOVA Iovance Biotherapeutics, Inc.

$8.80 +2.09%

Updated

Healthcare · Biological Products, (No Diagnostic Substances)

Iovance Biotherapeutics, Inc. (IOVA) is a healthcare company in the Biological Products, (No Diagnostic Substances) industry, with a market capitalization of $4.0 billion. Shares last traded at $8.80, 6.0% below their 52-week high. Over the past year the stock is up 298.2%. Net profit margin is -89.1%, below the peer median of 5.3%. Revenue grew 60.6% year over year.

Market Cap
$4.0B
Shares Out
453.0M
EPS (TTM)
$-1.53
P/E Ratio
P/S Ratio
12.27
P/B Ratio
5.42
Dividend / Share
Dividend Yield
52-Week High
$9.36
52-Week Low
$1.76
Volume
641,214
Avg Vol (3m)
817,866.429

Performance

1W
+6.41%
1M
+103.70%
3M
+100.00%
6M
+91.30%
YTD
+249.21%
1Y
+298.19%

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
70.31
SMA (50)
$5.80
SMA (200)
$3.90
Price vs SMA50
+51.65%
Price vs SMA200
+125.83%
ATR (14)
$0.53

Full technical analysis (26 indicators, D/W/M) →

Financials

Revenue
$325M
Net Income
$-290M
Gross Margin
48.4%
Operating Margin
-92.7%
Net Margin
-89.1%
Return on Equity
-39.3%
Return on Assets
-31.6%
Current Ratio
4.35
Debt / Equity
0.24
Revenue Growth (YoY)
+60.6%

Latest reported annual period ending 2026-06-30 · SEC EDGAR/XBRL.

Full financials — revenue, cash flow & debt over time →

Recent earnings

PeriodEPS (diluted)Reported
Q2 2026 $-0.29 2026-08-06
Q1 2026 $-0.19 2026-05-07
FY 2025 $-1.09 2026-02-24
Q2 2026 $-0.69 2026-08-06
Q1 2026 $-0.36 2026-05-07
FY 2025 $-1.28 2026-02-24

Full earnings history →

Biological Products, (No Diagnostic Substances) peers

IOVA vs 14 industry peers (Biological Products, (No Diagnostic Substances)), by market cap. Updated

P/S vs peers
12.27 / 19.49 med
-37% discount
Net margin vs peers
-89.1% / 5.3% med
below median
1–14 of 14
AMGNAmgen$240.1B27.476.3023.0%+0.31%
GILDGilead Sciences$187.5B-57.876.16-10.6%+1.09%
MRNAModerna$58.8B-18.68-1.94%
RVMDRevolution Medicines, Inc.$45.2B-25.55+0.76%
BIIBBiogen$33.1B24.163.3413.8%+0.78%
NBIXNeurocrine Biosciences Inc$16.1B22.814.7720.9%+0.33%
EXELExelixis, Inc.$14.7B17.036.0235.3%+1.00%
HALOHalozyme Therapeutics, Inc.$12.6B30.397.5524.9%+1.01%
TECHBio-Techne$11.4B62.489.3515.0%+0.21%
KRYSKrystal Biotech, Inc.$11.0B45.5224.9554.8%+0.58%
APGEApogee Therapeutics, Inc.$10.2B-34.57+0.04%
KYMRKymera Therapeutics, Inc.$9.7B-32.51-1.24%
RGENRepligen Corp$9.6B230.5312.205.3%-1.87%
PCVXVaxcyte, Inc.$9.1B-8.56-0.62%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.